Key Highlights

  • POMDOCTOR is trading 69.06% higher at $2.35, the largest move of the five.
  • Karyopharm is trading 27.46% higher at $0.61, with a lender forbearance period running to November 1, 2026.
  • Pulmonx is trading 27.27% higher at $2.52 after third-quarter revenue of $22.8 million.
  • Pacific Biosciences of California is trading 22.24% higher at $3.00 ahead of third-quarter results on November 4, 2026.
  • Chanson International is trading 9.26% higher at $1.18, with first-half net income of $0.8 million.

Which Penny Stocks Are Trading Higher on Wednesday, October 28, 2026?

Five penny stocks are trading higher on Wednesday, October 28, 2026. POMDOCTOR (NASDAQ:POM) is trading 69.06% higher at $2.35 after an ADR termination and share consolidation, Karyopharm (NASDAQ:KPTI) is trading 27.46% higher at $0.61 under a debt forbearance deadline, and Pulmonx (NASDAQ:LUNG) is trading 27.27% higher at $2.52 after third-quarter results. Pacific Biosciences of California (NASDAQ:PACB), known as PacBio, is trading 22.24% higher at $3.00, and Chanson International (NASDAQ:CHSN) is trading 9.26% higher at $1.18. Only Pulmonx has a dated report that plausibly bears on its move.

The ranking is by the size of today's percentage move, one basis shared by all five. Karyopharm and Pulmonx are only 0.19 percentage points apart (calculated). Each section below condenses one stock, followed by calculated comparisons and the dated events ahead.

1. POMDOCTOR: What Is Behind the 69.06% Jump Without a New Announcement?

POMDOCTOR is trading 69.06% higher at $2.35, which implies a prior close of about $1.39 (calculated), compared with a reported close of $1.13 on Monday, October 26, 2026. No dated company release accompanied the move. The Guangzhou-based digital healthcare business runs internet hospitals, an online pharmacy and a pharmaceutical supply chain.

The share structure changed this month. The ADR program was set to end on October 21, 2026, with Class A ordinary shares trading directly on Nasdaq, and every 10 ordinary shares were consolidated into 1. Nasdaq staff issued a delisting determination on October 6, 2026 after 30 consecutive business days below $1.00, and the company said it intended to request a hearing, which stays the suspension if timely.

2. Karyopharm: Why Is a Distressed Drugmaker Trading 27.46% Higher?

Karyopharm is trading 27.46% higher at $0.61, from a close of $0.4821 on Monday, October 26, 2026, which followed a 6.84% decline that day. No dated company release accompanied the move. The Massachusetts drugmaker's main marketed product is the cancer medicine XPOVIO, and its equity is valued at roughly $13.8 million (calculated) on about 22.68 million shares.

The forbearance period with noteholders was extended on October 22 to November 1, 2026, and the filings give only dates, not terms. Cash was $55.0 million at June 30, 2026, plus $10.1 million of investments, against $69.5 million of scheduled debt payments over the following twelve months, and the quarterly report flagged going-concern doubt. Short interest was 7,266,973 shares for the settlement date of October 15, 2026, about 32% of shares outstanding (calculated) and 4.84 days to cover.

3. Pulmonx: Did Third-Quarter Revenue Growth Drive the 27.27% Move?

Pulmonx is trading 27.27% higher at $2.52, which implies a prior close of about $1.98 (calculated). The most likely catalyst is the third-quarter release of Tuesday, October 27, 2026, though that link is an inference from timing. The medical device maker's Zephyr Endobronchial Valve treats severe emphysema.

Third-quarter revenue was $22.8 million, up 6% from $21.5 million, and the net loss narrowed to $8.4 million, or $0.19 per share, from $14.0 million. Operating expenses fell 18% to $24.9 million, and full-year revenue guidance of $90 million to $92 million was held. Cash was $52.7 million at September 30, 2026, down from $69.8 million at year-end 2025, against about $37.8 million of debt, and China contributed no revenue.

4. PacBio: What Is Behind a 22.24% Move With No Dated Release?

PacBio is trading 22.24% higher at $3.00, which implies a prior close of about $2.45 (calculated). No dated company release accompanied the move. The Menlo Park company makes DNA sequencing systems built around long-read technology, and on October 19, 2026 it announced a multi-year collaboration with Verily Health.

Second-quarter 2026 revenue was $39.0 million, and full-year guidance stands at $155 million to $165 million. Cash and investments were $236.9 million at June 30, 2026, against $644.3 million of convertible senior notes. Short interest is 47.22 million shares, or 15.53% of the float, with 4.51 days to cover, from the latest available reading.

5. Chanson International: Can a Bakery Chain's 9.26% Gain Be Explained?

Chanson International is trading 9.26% higher at $1.18, which implies a prior close of about $1.08 (calculated), with no dated release. The company sells baked goods, cakes, pastries and mooncakes through its own stores in China and the United States. Trading is thin, so small order flow can move the price by several percent.

First-half 2026 revenue was $8.3 million, down 4.5%, yet net income was $0.8 million against a $1.0 million loss a year earlier. Cash was $20.0 million at June 30, 2026, while the market value at $1.18 is about $2.7 million (calculated) on 2,322,391 shares. A 100-for-1 share consolidation took effect on May 7, 2026.

Penny Stock Gainers Compared: How Wide Are the Gaps in Moves and Balance Sheets?

POMDOCTOR's 69.06% gain is 41.60 percentage points above Karyopharm's 27.46% and 59.80 points above Chanson's 9.26% (calculated). In dollar terms, POMDOCTOR's rise is about $0.96 a share against about $0.10 for Chanson (calculated), using the implied prior closes.

Debt is shown on different dates. PacBio's convertible notes of $644.3 million exceed its cash and investments of $236.9 million by $407.4 million, and Karyopharm's debt of about $249.9 million exceeds its $65.1 million of cash and investments by about $184.8 million, both at June 30, 2026 (calculated). Pulmonx's cash of $52.7 million at September 30, 2026 exceeds its $37.8 million of debt by $14.9 million (calculated).

What to Watch Next: November 1 Forbearance Deadline, November 4 PacBio Report and the Nasdaq Hearing

Karyopharm's forbearance period runs to November 1, 2026 unless extended again or ended early, and its third-quarter results are estimated for around November 6. PacBio reports third-quarter results on November 4, 2026. POMDOCTOR awaits the outcome of its Nasdaq hearing request, Pulmonx has no announced date for its fourth-quarter report, which must reach roughly $23.8 million to $25.8 million (calculated) to fit full-year guidance, and Chanson's next scheduled disclosure is full-year 2026 results.